Veradermics’ VDPHL01 Phase 2 Trial Met Key Endpoints In Female Pattern Hair Loss, Showing Rapid Onset Of Hair Growth, 88.9%–90.0% Patient‑Reported Improvement At Month 6; Topline Phase 2/3 Study 306 Results Expected In H1 2027

Loading news article.

Veradermics’ VDPHL01 Phase 2 Trial Met Key Endpoints In Female Pattern Hair Loss, Showing Rapid Onset Of Hair Growth, 88.9%–90.0% Patient‑Reported Improvement At Month 6; Topline Phase 2/3 Study 306 Results Expected In H1 2027 | WAPE

Veradermics’ VDPHL01 Phase 2 Trial Met Key Endpoints In Female Pattern Hair Loss, Showing Rapid Onset Of Hair Growth, 88.9%–90.0% Patient‑Reported Improvement At Month 6; Topline Phase 2/3 Study 306 Results Expected In H1 2027

Article summary

Related companies

Comments —